Gilead Sciences to Present at Upcoming Investor Conference
Gilead Sciences (NASDAQ: GILD) has announced its participation in the upcoming J.P. Morgan Healthcare Conference scheduled for January 13, 2025. The presentation will begin at 11:15 a.m. Pacific Time and will be accessible via live webcast on investors.gilead.com, with replay available for at least 30 days.
Gilead Sciences is a biopharmaceutical company with over three decades of breakthrough medical achievements. The company focuses on developing innovative medicines for life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Operating in more than 35 countries worldwide, Gilead is headquartered in Foster City, California.
Gilead Sciences (NASDAQ: GILD) ha annunciato la sua partecipazione alla prossima J.P. Morgan Healthcare Conference, programmata per il 13 gennaio 2025. La presentazione avrà inizio alle 11:15 ora del Pacifico e sarà accessibile tramite webcast dal vivo su investors.gilead.com, con replay disponibile per almeno 30 giorni.
Gilead Sciences è un'azienda biofarmaceutica con oltre tre decenni di risultati medici innovativi. L'azienda si concentra sullo sviluppo di farmaci innovativi per malattie potenzialmente letali, tra cui HIV, epatite virale, COVID-19 e cancro. Operando in oltre 35 paesi nel mondo, Gilead ha sede a Foster City, California.
Gilead Sciences (NASDAQ: GILD) ha anunciado su participación en la próxima J.P. Morgan Healthcare Conference programada para el 13 de enero de 2025. La presentación comenzará a las 11:15 a.m. hora del Pacífico y estará disponible a través de una transmisión en vivo en investors.gilead.com, con reproducción disponible durante al menos 30 días.
Gilead Sciences es una empresa biofarmacéutica con más de tres décadas de logros médicos innovadores. La empresa se centra en desarrollar medicamentos innovadores para enfermedades potencialmente mortales, incluyendo VIH, hepatitis viral, COVID-19 y cáncer. Operando en más de 35 países en todo el mundo, Gilead tiene su sede en Foster City, California.
길리어드 사이언스(Gilead Sciences) (NASDAQ: GILD)는 오는 J.P. 모건 헬스케어 컨퍼런스에 참여할 것이라고 발표했습니다. 이 행사는 2025년 1월 13일에 예정되어 있으며, 발표는 태평양 표준시 기준으로 오전 11시 15분에 시작됩니다. 해당 발표는 investors.gilead.com에서 실시간 웹캐스트로 시청할 수 있으며, 재생은 최소 30일 동안 가능합니다.
길리어드 사이언스는 30년 이상의 혁신적인 의학 성과를 가진 생물 제약 회사입니다. 이 회사는 HIV, 바이러스성 간염, COVID-19 및 암을 포함한 생명을 위협하는 질병에 대한 혁신적인 의약품 개발에 중점을 두고 있습니다. 전 세계 35개국 이상에 운영되며, 본사는 캘리포니아주 포스터 시티에 있습니다.
Gilead Sciences (NASDAQ: GILD) a annoncé sa participation à la prochaine J.P. Morgan Healthcare Conference prévue pour le 13 janvier 2025. La présentation commencera à 11h15, heure du Pacifique, et sera accessible via un webinaire en direct sur investors.gilead.com, avec un replay disponible pendant au moins 30 jours.
Gilead Sciences est une entreprise biopharmaceutique avec plus de trois décennies de réalisations médicales remarquables. L’entreprise se concentre sur le développement de médicaments innovants pour des maladies potentiellement mortelles, y compris VIH, hépatite virale, COVID-19 et cancer. Présente dans plus de 35 pays dans le monde, Gilead a son siège à Foster City, Californie.
Gilead Sciences (NASDAQ: GILD) hat seine Teilnahme an der bevorstehenden J.P. Morgan Healthcare Conference angekündigt, die für den 13. Januar 2025 geplant ist. Die Präsentation beginnt um 11:15 Uhr pazifischer Zeit und wird über einen Live-Webcast auf investors.gilead.com zugänglich sein, mit einer Wiederholung, die für mindestens 30 Tage verfügbar ist.
Gilead Sciences ist ein biopharmazeutisches Unternehmen mit über drei Jahrzehnten bahnbrechender medizinischer Errungenschaften. Das Unternehmen konzentriert sich auf die Entwicklung innovativer Medikamente für lebensbedrohliche Krankheiten, darunter HIV, Virushepatitis, COVID-19 und Krebs. Gilead ist in mehr als 35 Ländern weltweit tätig und hat seinen Hauptsitz in Foster City, Kalifornien.
- None.
- None.
- J.P. Morgan Healthcare Conference on Monday, January 13, 2025 beginning at 11:15 a.m. Pacific Time
The live webcast can be accessed at investors.gilead.com and the replay will be available for at least 30 days following the presentation.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in
For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241220674353/en/
Jacquie Ross, Investors
Investor_relations@gilead.com
Source: Gilead Sciences, Inc.
FAQ
When is Gilead Sciences (GILD) presenting at the J.P. Morgan Healthcare Conference 2025?
How long will the replay of GILD's J.P. Morgan Healthcare Conference presentation be available?
What are the main therapeutic areas that GILD focuses on?
How many countries does GILD operate in globally?
Where can investors access GILD's J.P. Morgan Healthcare Conference presentation?
